InflaRx NVMEX:IFRXN 30 ROE % is -56.70% as of Mar. 2026. GuruFocus rates MEX:IFRXN with a GF Score™ of 30/100. The stock has 5 warning signs investors should review. Among 1,255 Biotechnology companies, InflaRx NV ranks worse than 71.79% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. InflaRx NV's annualized net income for the quarter that ended in Mar. 2026 was MXN-466.39 Mil. InflaRx NV's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was MXN822.62 Mil. Therefore, InflaRx NV's annualized ROE % for the quarter that ended in Mar. 2026 was -56.70%.
The historical rank and industry rank for InflaRx NV's ROE % or its related term are showing as below:
MEX:IFRXN'
s ROE % Range Over the Past 10 Years
Min: -94.6 Med: -45.29 Max: -21.63
Current: -87.15
During the past 11 years, InflaRx NV's highest ROE % was -21.63%. The lowest was -94.60%. And the median was -45.29%.
MEX:IFRXN's ROE % is ranked worse than 71.79% of 1255
companies
in the Biotechnology industry
Industry Median: -38.18
vs MEX:IFRXN: -87.15
InflaRx NV (MEX:IFRXN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
InflaRx NV ROE % Related Terms
InflaRx NV ROE % Historical Data
* Premium members only.
The historical data trend for InflaRx NV's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, InflaRx NV's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InflaRx NV ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InflaRx NV's ROE % distribution charts can be found below:
* The bar in red indicates where InflaRx NV's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
InflaRx NV (MEX:IFRXN) has a ROE % of -56.70% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on InflaRx NV and its competitors. According to the industry distribution chart, InflaRx NV ranks #901 out of 1255 companies in the Biotechnology industry, placing it in the top 71.8%.
Is InflaRx NV's ROE % too high?
InflaRx NV's current ROE % is -56.70%. Based on the distribution chart, InflaRx NV ranks #901 out of 1255 companies in the Biotechnology industry, which is below the industry midpoint. Overall, InflaRx NV has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's ROE % compare to IRD and NAUT?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #901 out of 1255 companies for ROE %. This places InflaRx NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on InflaRx NV and its competitors. InflaRx NV's current ROE % is -56.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (MEX:IFRXN) has a current ROE % of -56.70%. The current ROE % is -56.70%. InflaRx NV's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For InflaRx NV (MEX:IFRXN), the current ROE % is -56.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
30GF Score
Get the complete analysis for MEX:IFRXN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IFRXN has been successfully added to your 
